Aarti Drugs Limited has announced its consolidated financial results for Q3 FY25, reporting revenue from operations of ₹556.6 crore, marking a YoY decline of 8.1% from ₹606.94 crore in Q3 FY24 and a QoQ decline of 7% from ₹598.33 crore in Q2 FY25. The company’s net profit stood at ₹37.09 crore, reflecting a flat show from ₹36.71 crore and a QoQ increase of 6.1% from ₹34.96 crore in Q2 FY25.
Key Financial Highlights for Q3 FY25:
- Revenue from operations: ₹556.6 crore (-8.1% YoY, -7% QoQ)
- Total income: ₹568.5 crore (-6.5% YoY, -5.2% QoQ)
- Total expenses: ₹517.7 crore (-3.4% YoY, -6.8% QoQ)
- EBITDA: ₹50.76 crore (-1.5% YoY, +10.7% QoQ)
- Profit before tax (PBT): ₹50.76 crore (-1.5% YoY, +10.7% QoQ)
- Net Profit (PAT): ₹37.09 crore
Performance Overview:
- The cost of materials consumed stood at ₹369.79 crore, forming the largest component of the company’s expenses.
- Depreciation and amortization expenses were at ₹115.72 crore, showing a slight increase from the previous quarter.
- Finance costs stood at ₹13.8 crore.
- Tax expenses for the quarter were ₹13.67 crore.
Despite the YoY decline in revenue, the company has managed to improve its QoQ profitability, driven by cost optimization and operational efficiencies. Aarti Drugs remains focused on expanding its product portfolio while navigating industry challenges.
